SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy.

Gregory E EdelsteinJulie BoucauRockib UddinCaitlin MarinoMay Y LiewMamadou BarryManish C ChoudharyRebecca F GilbertZahra ReynoldsYijia LiDessie TienShruti SagarTammy D VyasYumeko KawanoJeffrey A SparksSarah P HammondZachary WallaceJatin M VyasAmy K BarczakJacob E LemieuxJonathan Z LiMark J Siedner

Published in: medRxiv : the preprint server for health sciences (2023)

Virologic rebound occurred in approximately one in five people taking nirmatrelvir-ritonavir and often occurred without worsening symptoms. Because it is associated with replication-competent viral shedding, close monitoring and potential isolation of those who rebound should be considered.

Keyphrases

sars cov
antiretroviral therapy
hiv infected
respiratory syndrome coronavirus
risk assessment
stem cells
human health
bone marrow
cell therapy
physical activity